Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 12:40 AM
NCT ID:
NCT03119467
Eligibility Criteria:
Inclusion Criteria:
* Refractory to or relapsed after at least 1 prior treatment line.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2
* Patients must be ≥18 years of age
* Able to give a written informed consent.
Exclusion Criteria:
* Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).
* Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
* Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.
* Patients with graft versus-host disease (GVHD)
* Subjects who have received drugs that directly or indirectly inhibit calcineurin or Nuclear Factor of activated T cells (NFAT) activity .
* Patient with symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV);
* Patient with Frederica's (QTcF) formulas (QTcF) ≥450 msec;
* Patient with angina not well-controlled by medication;
* Women who are pregnant or lactating.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03119467
Study Brief:
Protocol Section:
NCT03119467